Summary: <p>Jennifer Quint (Thorax’s journal club editor) talks to Dr John Matthews (Genentech) about his New England Journal of Medicine published study into whether lebrikizumab, an interleukin-13 monoclonal antibody, can improve asthma control.</p><p>Dr Matthews explains the proposed mechanism behind the treatment and how they found it increased FEV1 in adults for whom inhaled glucocorticoids didn’t control their asthma - especially in those with high periostin levels.</p><p>Dr Matthews was involved in the Milly trial. This podcast is intended for healthcare professionals only.</p><p>See also:</p><p>http://www.nejm.org/doi/full/10.1056/NEJMoa1106469</p>
